PTK2 and head and neck squamous cell carcinoma: It was also shown that FAK inhibition sensitizes tumors for RT in the preclinical models of other malignancies including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and breast cancer22–24.